House FDA Hearing: No Plan for Domestic Drug Manufacturing
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
Made in USA Pharma Supply Chain Amendment Passes Unanimously
Sen. Tina Smith’s bill to provide $500 million in grants for domestic pharmaceutical manufacturers passes with flying colors and will be part of PREVENT Pandemics Act.
House Hearing on FDA: Advanced Manufacturing May – or May Not – Lead to Domestic Manufacturing Boom
The House Committee on Energy and Commerce discussed FDA’s user fee budget and what can be done to reshore more of the pharmaceutical industry.
CPA Letter to House Leadership Regarding Procuring “Made in China” Masks
CPA sent the following letter to House Speaker Nancy Pelosi (D-CA) and Minority Leader Kevin McCarthy (R-CA) regarding the Office of the Attending Physician’s distribution of KN95 masks made in China to lawmakers. CPA urged House leadership to immediately stop all purchase and procurement of Chinese personal protective equipment (PPE) and instead source from American…
Covid Supply Chain Crunch: Asian-Made PPE Stuck at Ports, Supplies Late
Recent supply chain bottlenecks of hospital gear shows why continued dependence on Asia is bad for pandemic preparedness. The Make PPE in America Act in the infrastructure law should remedy this in the years ahead, if Congress doesn’t open the doors to duty-free PPE and undercut the law’s intent.
Global Pharma Supply Chain Survey Shows Free Trade Not The Solution
Free trade loses out to a bigger government role in securing domestic supply chains of critical medication.
CPA Applauds Brown, Baldwin Letter to USTR Tai Urging Support of U.S. PPE Production & to End Tariff Exclusions on Chinese PPE
WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded U.S. Senators Sherrod Brown (D-OH) and Tammy Baldwin (D-WI) for leading a letter to United States Trade Representative (USTR) Katherine Tai requesting that 301 penalty duties be assessed to all imported finished state personal protective equipment (PPE) and key raw material inputs, including single-use…
Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman
CPA’s report, titled “Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman,” details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign…
New CPA Report Documents How Hatch-Waxman Act Loophole Led to Offshoring of Generics Production, Price Gouging, and Shortages
WASHINGTON — The Coalition for a Prosperous America (CPA) today released a new academic report that details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign companies in the U.S. The…
‘Made in America’ Pandemic Preparedness Act Passes Committee Unanimously. Now What?
Both houses of Congress have bills that have passed committees, easily, in regard to building domestic supply of personal protective equipment for medical staff. These bills need to hit the floor so President Biden can sign them. But, more importantly, Buy American provisions face serious WTO risk, making all of this action moot.